VL/HCC 2024
Mon 2 - Fri 6 September 2024 Liverpool, United Kingdom

Artificial intelligence (AI) has attracted many researchers to improve healthcare. Advances in machine learning along with availability of large medical datasets has driven development of innovative applications to accelerate drug discovery and development. In this talk, Nikolay will highlight the potential of AI including generative AI through several recent pharmaceutical use cases. He will present current challenges of building interfaces between pathologists and AI applications including explainability, interpretability, potential bias, and ethical considerations.

Dr Nikolay Burlutskiy is Director of Artificial Intelligence at AstraZeneca R&D, UK. His interest is in developing trustworthy AI models for domain experts, such as pathologists and imaging experts, to improve and accelerate drug discovery and development processes. Nikolay has background in computer science with a PhD in machine learning and deep learning. Prior to AstraZeneca, he was leading algorithm development of Inify, a successful decision support tool to empower pathologists, at ContextVision in Stockholm. He also worked as R&D AI engineer at Samsung Electronics in South Korea developing vacuum cleaning robots. He co-authored over 25 peer-reviewed publications including several US patents on AI applications.